Here's another exercise where we give Chat GPT the ~600 current PLA codes and we ask it to find rhyme or reason in their multitudes. The text and the analysis below are entirely machine-written with minimal instructions from me.
###
Here are AMA CPT PLA codes up to code 0659U. Some codes have been deleted, so the active file contains 583 lines rather than 659 separate items.
Study them and discuss them for my blog readers. Then assess the codes in categorized groups, using categories that seem reasonable to you. I suggest using no more than ten categories, including an “Other” category. Some codes may fit more than one category; in those cases, use a “best fit” principle.
###
Bruce, Here’s a blog-ready version based on the uploaded workbook. I also created an annotated workbook with the added category column and a summary sheet:
PLA codes categorized summary. [not a live link]
(BQ: See tables in Google Cloud here. Note that there are 2 tabs.)
A Field Guide to the PLA Code Universe:0001U Through 0659U
The AMA’s PLA code series has become a kind of public fossil record of modern proprietary diagnostics. The file reviewed here runs through code 0659U. Although the numerical series reaches 659, the active workbook contains 583 rows and 581 unique HCPCS codes. Two rows, 0563U and 0564U, appear twice in the file. Thus, 78 code numbers in the 0001U–0659U range are absent from this active list, presumably because of deletions or gaps.
The PLA universe is not one thing. It includes ordinary-looking infectious disease panels, high-priced oncology assays, whole-genome sequencing, transplant rejection tests, pharmacogenomic assays, drug monitoring tests, digital pathology tests, and a growing number of algorithmic risk scores. The unifying feature is not clinical domain, but commercial and operational form: these are proprietary laboratory analyses, usually tied to a particular test developer, platform, algorithm, or test configuration.
For this review, I grouped the 581 unique active codes into ten “best-fit” analytic categories. These are not AMA official categories. They are intended as a practical map for readers trying to understand what the PLA code series has become.
| Category | Unique codes | Share | Median positive CLFS rate |
|---|---|---|---|
| Oncology — screening, diagnosis, risk & prognosis | 112 | 19.3% | $900 |
| Oncology — treatment selection, genomic profiling & MRD | 98 | 16.9% | $1,744 |
| Infectious disease, microbiome & antimicrobial resistance | 81 | 13.9% | $263 |
| Germline, reproductive, rare disease & pharmacogenomics | 79 | 13.6% | $787 |
| Hematology, transfusion medicine & coagulation | 61 | 10.5% | $275 |
| Organ-system medicine, autoimmune & chronic disease | 61 | 10.5% | $261 |
| Neurology, psychiatry & neurodegeneration | 50 | 8.6% | $541 |
| Toxicology, medication adherence & drug monitoring | 22 | 3.8% | $199 |
| Transplant, histocompatibility & immune monitoring | 16 | 2.8% | $2,753 |
| Other / methodology / miscellaneous | 1 | 0.2% | $760 |
The two oncology categories together account for 210 of the 581 unique codes, or about 36%. That is the central fact about the PLA code series. Oncology dominates, but it does so in two different ways. One group consists of diagnostic, prognostic, screening, and recurrence-risk tests: prostate risk scores, breast cancer recurrence classifiers, thyroid nodule classifiers, pancreatic cyst tests, skin cancer risk tests, and other assays that try to place a patient into a clinical risk category. The other group consists of treatment-selection tests: broad tumor genomic profiling, liquid biopsy, resistance mutation testing, companion-diagnostic-like assays, and MRD-style monitoring.
The price pattern is also revealing. Oncology treatment-selection and genomic-profiling codes have a median positive rate of about $1,744. Oncology risk/prognosis tests have a lower median, about $900, but with some very high outliers. The highest positive rate in the file is $8,500 for 0315U, a cutaneous squamous cell carcinoma gene-expression profile. The second highest is $8,455 for 0211U, a pan-tumor DNA/RNA next-generation sequencing assay.
The germline, reproductive, rare disease, and pharmacogenomic category is another major block, with 79 codes. This category includes carrier and reproductive genetics, whole-exome and whole-genome sequencing for constitutional disease, mitochondrial disease testing, pharmacogenomic drug-metabolism tests, and rare disease diagnostics. Its median rate is about $787, but the mean is much higher because rapid and ultrarapid whole-genome sequencing codes sit in the several-thousand-dollar range.
Infectious disease is large by code count but lower by price. The 81 infectious disease, microbiome, and antimicrobial-resistance codes have a median positive rate of about $263. This category includes respiratory panels, STI and urinary tract infection assays, H. pylori resistance testing, tick-borne disease serology, fungal and bacterial sequencing, and broader pathogen identification panels. This is a useful contrast with oncology: infectious disease contributes many codes, but usually not the very high-dollar codes.
Transplant is the opposite pattern. There are only 16 transplant, histocompatibility, and immune-monitoring codes, but the median positive rate is about $2,753, the highest median of any category. These include donor-derived cell-free DNA, rejection monitoring, histocompatibility/HLA-related assays, and transplant immune surveillance. In reimbursement terms, this is a small but high-value and high-scrutiny zone.
The hematology/transfusion/coagulation category is larger than casual readers might expect. It includes red-cell antigen genotyping, sickle cell assays, von Willebrand-related tests, platelet and bleeding-disorder genetics, thrombosis risk, and other blood-disease tests. Many of these are not “hot” venture-capital diagnostics, but they show how PLA codes are also used for highly specialized laboratory configurations in established medical niches.
The organ-system medicine category is a catch-all for tests that are clinically specific but not oncology, infection, transplant, or neurology. It includes cardiovascular risk, lipid and metabolic tests, kidney and liver tests, GI and inflammatory bowel disease assays, thyroid and endocrine tests, obstetric tests, autoimmune markers, allergy/asthma-related tests, ophthalmology, dermatology, pain-related biomarkers, and related chronic-disease diagnostics. This group has 61 codes and a modest median positive rate of about $261.
Neurology, psychiatry, and neurodegeneration now form a substantial PLA category, with 50 codes. This includes Alzheimer’s-related amyloid and tau tests, Parkinson’s and neurodegeneration markers, autism and ADHD-related assays, psychiatric pharmacologic or behavioral classifiers, seizure and ataxia genetics, and neuroimmune antibody tests. The median positive rate is about $541. This is a category to watch because neurology has historically lagged oncology in molecular diagnostics, but the PLA list shows it becoming more commercially active.
The toxicology, medication adherence, and drug-monitoring category is smaller, with 22 codes. It includes drug testing, prescription drug monitoring, medication adherence assays, opioid-related tests, tenofovir monitoring, and PFAS/environmental exposure testing. These codes are generally lower-priced, although there are outliers.
A cross-cutting view is just as important as the clinical category view.
- Across the 581 unique codes,
- 178 descriptors contain algorithm or risk-score type language.
- About 186 involve sequencing or genomic sequence analysis.
- About 115 mention RNA, mRNA, microRNA, transcriptome, or gene-expression methods.
- Forty-three mention cell-free DNA or circulating tumor DNA.
- Thirty-nine mention methylation.
- Forty-three mention mass spectrometry or LC-MS/MS.
- In other words, the PLA series is not merely a list of branded lab tests; it is a running catalog of the technological motifs in advanced diagnostics.
Gapfill = $0
One final reimbursement note: 75 unique codes in the workbook have a RATE value of $0.00. These zero-rate codes were excluded from the rate medians and means above. All 0600U–0659U codes in this workbook show a zero rate, and 15 codes in the 0500U–0599U range also show zero. That pattern strongly suggests that many recent codes are present in the code file before a stable CLFS price is reflected in the workbook. (BQ: They are in "Gapfill" usually.)
The overall median positive rate across the unique, positively priced PLA codes is about $635. The mean is much higher, about $1,173, because high-priced oncology, transplant, and whole-genome sequencing tests pull the average upward. That skew is one of the most important reimbursement lessons in the file: PLA codes range from very low-cost immunoassays and infectious disease tests to multi-thousand-dollar genomic and algorithmic products.
For blog readers, the main takeaway is this: the PLA code series has become the CPT system’s front door for proprietary diagnostics, but the house behind that door is sprawling. Oncology is the largest tenant. Rare disease genomics, infectious disease, transplant monitoring, neurology, pharmacogenomics, and chronic-disease risk scores all occupy important rooms. The result is a code family that looks deceptively simple from the outside — 0001U, 0002U, 0003U — but actually contains the entire modern diagnostic economy in miniature.
